Abstract
IntroductionVedolizumab is licenced for treatment of moderate-to-severe ulcerative colitis(UC) and Crohn’s disease(CD) after failure of conventional or anti-TNF therapy. Clinical trial data from the GEMINI studies reported a Wk 6...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
